

# Beating Cancer with Highly Innovative Technologies – What’s the role of RWE?

Tuesday 18 April 2023 | 15.00 – 16.30 CEST

## SPEAKER BIOGRAPHIES

### **Karen Facey** (co-moderator)

Evidence Based Health Policy Consultant to FIPRA, member of the RWE4Decisions Secretariat



Karen Facey worked as a senior statistician in the pharmaceutical sector and UK medicines regulation, before becoming the founding Chief Executive of the first national HTA agency in Scotland. Since 2003, Dr Facey has been an independent consultant on health policy, HTA and patient involvement. She has served as Non-Executive Director on Scottish health boards and led research at the University of Edinburgh on appraisal of rare disease treatments in the IMPACT HTA project. She is passionate about holistic HTA to determine value and use of health service data to improve patient care. Karen Facey has facilitated the development of the RWE4Decisions multi-stakeholder initiative and is the lead author of the

paper on ‘Real-World Evidence to Support Payer/HTA Decisions about Highly Innovative Technologies in the EU – Actions for Stakeholders’, commissioned by the Belgian payer INAMI-RIZIV. As of April 2023, she is a Senior Adviser to FIPRA International, advising on HTA projects, as well as being part of the RWE4Decisions Secretariat.

### **Matti Aapro** (co-moderator)

Medical Oncologist, Genolier Cancer Centre & Immediate Past-President, European Cancer Organisation



Matti Aapro is a member of the Board of Directors of the Genolier Cancer Centre and the Immediate Past-President of the European Cancer Organisation. Dr. Aapro is an Executive Board member of *All.Can* and the President of *Sharing Progress in Cancer Care* (SPCC), both not-for-profit associations. He notably serves the International Society for Geriatric Oncology (SIOG) as an Executive Board Member and is the past-President of the *Multinational Association for Supportive Care in Cancer* (MASCC). He continues to collaborate with the *European School of Oncology* (ESO) where he is a Scientific Advisory Board member. He is also a member of the Board

of the *French-speaking Society for Supportive Care* (AFSOS), as well as an Advisor to the *Japanese Association for Supportive Care in Cancer* (JASCC). He has been Board member of the *European Organization for Research and Treatment of Cancer* (EORTC) and of the Board of the European Society of Medical Oncology (ESMO). He received his medical degree from the University of Geneva and was a fellow at the Arizona Cancer Centre in Tucson, Arizona. He was the founding chair of the Medical and Radiation Therapy Department at the European Institute of Oncology in Milan. His main interests are Breast Cancer, Cancer in the Elderly, Supportive care and access to treatment.

**Prof. Christine Chomienne**

Professor of Cellular Biology at the Université de Paris, Vice-chair of the EU Cancer Mission



Professor Christine Chomienne is currently a Vice-Chair of the Horizon Europe Mission Board for Cancer and a Professor of Cellular Biology at the Paris Diderot University, from where she qualified in Medicine and holds her PHD. Prior to this, she was the Director of Research and Innovation at the *French National Cancer Institute* (INCa) and Director of the *French Cancer Institute* (Inserm), and a past president of the European Hematology Association. A physician specialized in Hematology, she has served on many scientific and clinical committees focused on Leukemia, Immunology, Oncology and Stem Cell Research. She was notably Head of the Cell

Biology Department at the Hôpital Saint Louis, Paris and Director of the University Inserm Research Laboratory at the Institut Universitaire d'Hématologie. Dr. Chomienne has also been involved in patient/parent participation in cancer research and in communication education on personalised medicine.

**MEP Tomislav Sokol (EPP, Croatia)**

Co-Rapporteur of the European Health Data Space for the Committee on Environment, Public Health and Food Safety (ENVI), European Parliament



MEP Tomislav Sokol joined the European Parliament in 2019 and has since been serving as member of the *Committee on the Internal Market and Consumer Protection* (IMCO) and of the *Special Committee on the Covid-19 pandemic* (COVI), as well as substitute for the *Committee on the Environment, Public Health, and Food Safety* (ENVI) and on the *Committee on Regional Development* (REGI). He is currently the ENVI Rapporteur on the European Commission's proposal for a *European Health Data Space*. Prior to his parliamentary activities, Sokol was appointed as Assistant Minister for Science and Technology at the Ministry of Science in Croatia and was the

Education Head of the Law Department. MEP Sokol also worked as an Assistant at the Law Department of the Zagreb School of Economics and Management. He graduated magna cum laude from the Faculty of Law of the University of Zagreb and pursued a Master's degree at the Katholieke Universiteit Leuven in Belgium, where he also defended his Ph.D dealing with free-movement of cross-border health care services in the EU. He is notably active in the MEP against Cancer Group and an active member of the European Alliance for Transformative Therapies (TRANSFORM) Interest Group.

### **Tanja Podkonjak**

Director, EUCAN Oncology Access and Reimbursement Policy, Takeda



Tanja Podkonjak has been working at Takeda for the past thirteen years, in Canada, the UK and currently in Switzerland. In 2021, she was appointed Director of the EUCAN Oncology and Reimbursement Policy, following her experience leading the Takeda Oncology market access team in the UK. Prior to this, she held various roles in market access, health economics, strategy and business operations across multiple countries. Tanja Podkonjak holds a Business Administration Master's Degree from the McMaster University, as well as a Master's degree in Economic Evaluation of Healthcare from the City University of London. She is a steering committee member of EFPIA's Oncology Platform. Her main interests are the access challenge of combination treatments, implementation of the EU HTA Regulation and the improvement of patient access as well as the use of Real-World Evidence for the assessment of cancer drugs.

### **Natacha Bolaños**

Head, Membership & Alliances, Lymphoma Coalition



Natacha Bolaños has significant experience in patient advocacy, education, and service provision in the field of cancer, both at national and European level. Before joining the Lymphoma Coalition Europe in September 2017, she successfully held Patient and Public affairs roles in cancer charities in Spain. She was appointed Board Member of the *European Cancer Patient Coalition* from 2016 to 2017 and is currently a member of the European Affairs Committee at the *European Haematology Association*. Natacha Bolaños has also been part of many health technology appraisal processes, and actively represents the patient voice in the *National Plan to Access Innovative Therapies* in Spain. She holds a degree in Cancer Rehabilitation Through Exercise Referral.

### **Emma Hernlund**

Analyst at the Swedish Dental and Pharmaceutical Benefits Agency (TLV)



Emma Hernlund is an Analyst at the Swedish national governmental authority, the Dental and Pharmaceuticals Benefits Agency (TLV). Prior to joining TLV, Emma worked more than 10 years at CROs developing health economic tools and performing RWD studies. She holds a MSc in Biomedicine and a PhD in experimental oncology from Karolinska Institutet.